



**Figure 4** Superposition of CypA complexes with the *cis* conformations of CA<sup>N</sup> and Suc-Ala-Ala-Pro-Phe-NA (ref. 23). Residues 88–91 of CA<sup>N</sup> AAA-B, green; Suc-Ala-Ala-Pro-Phe-NA, purple. Both ligands are shown truncated to C $\beta$ , except for proline and the tetrapeptide C-terminal nitrophenyl group. Residues of CypA that presumably move to allow the *trans* peptide substrate to contact Leu98 and Ser99 (bottom of figure) are shown explicitly<sup>25</sup>. These CypA residues and the protein substrate residues C-terminal to the isomeric proline are essentially unchanged in the *cis* and *trans* complexes of CA.

apparently with no space for a side chain and with ( $\phi$ ,  $\psi$ ) angles (+123°, +168°) that are favored only for glycine<sup>17</sup>. Consistent with this, the CA<sup>N</sup> G89A substitutions weaken the binding considerably; the  $K_d$  increases from ~20  $\mu$ M to ~500  $\mu$ M (ref. 18), with only slight variation in these values observed in a variety of sequence contexts (data not shown). The G89A substitution also shifts the equilibrium of the bound AAA species toward the *cis* conformation, with the result that both *cis* and *trans* structures are present in the same crystal (Table 1) and the *trans* conformation buries less deeply into the active site.

Remarkably, the AMA-A and AMA-A' complexes show a mixture of 80% *trans* and 20% *cis* conformations, each of which show close similarity to the fully occupied single conformation structures (Fig. 3a). Contact of the CA<sup>N</sup> *trans*-Ala89 C $\beta$  with CypA Arg55 (absent in the Gly89 structures) seems to hold the CA<sup>N</sup> Pro90 side chain ~1.5 Å away from its preferred binding positions for the Gly89 and *cis*-Ala89 structures (Figs. 2a and 3b). Thus, for a non-glycine residue preceding the substrate proline, movement from the *trans* conformation toward the transition state would relieve the steric clash with CypA Arg55 and allow optimal binding of the proline side chain (Fig. 3b).

Curiously, substitution of Gly89 to alanine in the AMA construct prompted a partial shift from the *cis* toward the *trans* conformation (Table 1). Comparison of the structures suggests that this results from intramolecular interactions within the CA<sup>N</sup> protein loop. The  $\psi$  angle of Gly89 is unfavorable for non-glycine residues at this position in the *cis*-AMG structure (where  $\psi$  = -163° and -176° for AMG-A and AMG-B, respectively). This potentially strained conformation is relieved in AMA-A/A' by partial switch to *trans* and by smaller adjustments to a  $\psi$  angle to +158° in *cis*-AMA-B/B'. The structures are therefore consistent with our earlier finding that CypA is a Gly-Pro-specific binding protein and support our proposal that, conversely, catalytic rates may be greatest for suboptimal binding sequences such as Ala-Pro<sup>17,18</sup>.

### Comparison to earlier proposals

The catalytic pathway proposed here for the CA protein substrate differs from the pathway for peptide substrates reported recently<sup>25</sup> on the basis of chemical shift and NMR relaxation

rate changes of main chain amides in the presence and absence of a model tetrapeptide substrate, Suc-Ala-Phe-Pro-Phe-NA, where Suc is succinyl and NA is *p*-nitroanilide. Catalytic pathways for both substrates seem to involve the same *cis* conformation, because all known CypA-*cis*-peptide structures overlap closely with the CypA-*cis*-Pro90 CA<sup>N</sup> structures described here, including a Suc-Ala-Ala-*cis*-Pro-Phe-NA substrate<sup>23</sup> that is closely related to the substrate used by Eisenmesser *et al.*<sup>25</sup> (Fig. 4). There are important differences, however, upon moving to the *trans* conformation. As described above, the CA<sup>N</sup> protein-substrate complex shows minimal conformational changes that are localized N-terminal to the isomeric proline. In contrast, the observation of catalysis-correlated relaxation rate changes at the main chain nitrogen atoms of CypA residues Leu98 and

Ser99 indicated that formation of the *trans* Suc-Ala-Phe-Pro-Phe-NA peptide complex involved substantial conformational changes in substrate and enzyme that position the substrate's C-terminal residues adjacent to CypA Leu98 and Ser99 (ref. 25). Curiously, the different pathway for Suc-Ala-Phe-Pro-Phe-NA does not seem to be simply the result of using a peptide substrate rather than protein, because structures of CypA bound to CA-derived hexapeptides<sup>19,20</sup> overlap closely with the *trans* CypA-CA<sup>N</sup> complexes.

A recent molecular dynamics study<sup>31</sup> of four tetrapeptides proposed the same transition-state geometry suggested here for the CA substrate. The crystallographic and dynamics studies are not in complete agreement, however, because the simulation suggested that both *cis* and *trans* ground-state structures bind with the peptide twisted ~20° from planarity, whereas we find that the X-Pro peptides of the protein substrate are not strongly twisted in the CypA crystal complexes with CA<sup>N</sup> (Table 2), nor even in the peptide used as a starting point in the simulations (see Methods). The average  $\omega$ -angle for the eight CA<sup>N</sup> *trans*-X-Pro90 peptides is just 0.2° away from a planar 180° angle (range 173°–190°), and this value increased to only 1.0° after refinement to convergence (sparse matrix, iterative conjugate gradient) in the absence of peptide planarity restraints. The eight *cis* conformations (excluding the 20% occupied structures) all show some twist (average 9.5°; range 2°–18°) toward the transition state, with an average value of 10.0° after refinement in the absence of peptide planarity restraints. Thus, the *trans*-X-Pro90 peptides are planar in CypA-CA<sup>N</sup>

**Table 2.**  $\omega$  angles of CA<sup>N</sup> Gly/Ala89-Pro90 peptide bond<sup>a</sup>

| <i>Trans</i> |  | HAG-A    | HAG-B    | AAG-A | AAG-B | AAA-A | AAA-A' | AMA-A | AMA-A' | Average |
|--------------|--|----------|----------|-------|-------|-------|--------|-------|--------|---------|
|              |  | 190.1    | 178.4    | 188.9 | 185.1 | 175.8 | 175.7  | 174.5 | 172.9  | 180.2   |
|              |  | 197.1    | 174.9    | 189.5 | 185.6 | 176.4 | 177.3  | 174.8 | 172.6  | 181.0   |
| <i>Cis</i>   |  | O-loop-A | O-loop-B | AMG-A | AMG-B | AAA-B | AAA-B' | AMA-B | AMA-B' | Average |
|              |  | 2.2      | 9.7      | 18.1  | 9.1   | 10.9  | 11.3   | 6.6   | 7.9    | 9.5     |
|              |  | 2.7      | 11.1     | 18.3  | 9.3   | 11.4  | 12.3   | 6.7   | 8.0    | 10.0    |

<sup>a</sup>Values shown are  $\omega$  angles in degrees as determined by PROCHECK<sup>42</sup>. Upper values are in the presence of standard stereochemical restraints. Lower values are after 30 cycles of refinement in the absence of planar restraints. In agreement with expected values<sup>43</sup>, the r.m.s. deviation from planarity of all peptides in the model ranges from 5.0° to 5.9° for the different refined structures.